Now showing items 1628-1647 of 4607

    • Free-View, 3D Gaze-Guided, Assistive Robotic System for Activities of Daily Living 

      Wang, M-Y; Kogkas, AA; Darzi, A; Mylonas, GP (IEEE, 2018-01-01)
    • Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). 

      Bellini, A; Pötschger, U; Bernard, V; Lapouble, E; Baulande, S; Ambros, PF; Auger, N; Beiske, K; Bernkopf, M; Betts, DR; Bhalshankar, J; Bown, N; de Preter, K; Clément, N; Combaret, V; Font de Mora, J; George, SL; Jiménez, I; Jeison, M; Marques, B; Martinsson, T; Mazzocco, K; Morini, M; Mühlethaler-Mottet, A; Noguera, R; Pierron, G; Rossing, M; Taschner-Mandl, S; Van Roy, N; Vicha, A; Chesler, L; Balwierz, W; Castel, V; Elliott, M; Kogner, P; Laureys, G; Luksch, R; Malis, J; Popovic-Beck, M; Ash, S; Delattre, O; Valteau-Couanet, D; Tweddle, DA; Ladenstein, R; Schleiermacher, G (2021-06-11)
      <h4>Purpose</h4>In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied <i>ALK</i> genetic alterations in high-risk ...
    • FRMD6 has tumor suppressor functions in prostate cancer. 

      Haldrup, J; Strand, SH; Cieza-Borrella, C; Jakobsson, ME; Riedel, M; Norgaard, M; Hedensted, S; Dagnaes-Hansen, F; Ulhoi, BP; Eeles, R; Borre, M; Olsen, JV; Olsen, JV; Thomsen, M; Kote-Jarai, Z; Sorensen, KD (2020-11-28)
      Available tools for prostate cancer (PC) prognosis are suboptimal but may be improved by better knowledge about genes driving tumor aggressiveness. Here, we identified FRMD6 (FERM domain-containing protein 6) as an aberrantly ...
    • From class waivers to precision medicine in paediatric oncology. 

      Pearson, ADJ; Pfister, SM; Baruchel, A; Bourquin, J-P; Casanova, M; Chesler, L; Doz, F; Eggert, A; Geoerger, B; Jones, DTW; Kearns, PR; Molenaar, JJ; Morland, B; Schleiermacher, G; Schulte, JH; Vormoor, J; Marshall, LV; Zwaan, CM; Vassal, G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium (2017-07)
      New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively ...
    • From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. 

      Hussain, SA; Birtle, A; Crabb, S; Huddart, R; Small, D; Summerhayes, M; Jones, R; Protheroe, A (2018-12)
      <h4>Context</h4>A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials.<h4>Obj ...
    • From fixed activities to personalized treatments in radionuclide therapy: lost in translation? 

      Flux, GD; Sjogreen Gleisner, K; Chiesa, C; Lassmann, M; Chouin, N; Gear, J; Bardiès, M; Walrand, S; Bacher, K; Eberlein, U; Ljungberg, M; Strigari, L; Visser, E; Konijnenberg, MW (2018-01)
    • From integrative genomics to therapeutic targets. 

      Natrajan, R; Wilkerson, P (2013-06-05)
      Combinatorial approaches that integrate conventional pathology with genomic profiling and functional genomics have begun to enhance our understanding of the genetic basis of breast cancer. These methods have identified key ...
    • From patent to patient: analysing access to innovative cancer drugs. 

      Sharpe, E; Hoey, R; Yap, C; Workman, P (2020-09)
      Analysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000-2016 shows that the number of authorisations increased over that timeframe. The median number of licensed drugs each year rose from six ...
    • From presentation to paper: Gender disparities in oncological research. 

      Dijksterhuis, WPM; Stroes, CI; Tan, W-L; Ithimakin, S; Calles, A; van Oijen, MGH; Verhoeven, RHA; Barriuso, J; Oosting, SF; Ivankovic, DK; Furness, AJS; Bozovic-Spasojevic, I; Gomez-Roca, C; van Laarhoven, HWM (2020-06)
      Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is ...
    • Functional and quality of life outcomes following obstetric anal sphincter injury (OASI): does the grade of injury affect outcomes? 

      Ramage, L; Yen, C; Qiu, S; Simillis, C; Kontovounisios, C; Tekkis, P; Tan, E (Springer Science and Business Media LLC, 2017-11)
    • Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. 

      Baxter, JS; Johnson, N; Tomczyk, K; Gillespie, A; Maguire, S; Brough, R; Fachal, L; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Ahearn, TU; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Augustinsson, A; Becher, H; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Bogdanova, NV; Bojesen, SE; Brenner, H; Brucker, SY; Cai, Q; Campa, D; Canzian, F; Castelao, JE; Chan, TL; Chang-Claude, J; Chanock, SJ; Chenevix-Trench, G; Choi, J-Y; Clarke, CL; NBCS Collaborators; Colonna, S; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Daly, MB; Devilee, P; Dörk, T; Dossus, L; Dwek, M; Eccles, DM; Ekici, AB; Eliassen, AH; Engel, C; Fasching, PA; Figueroa, J; Flyger, H; Gago-Dominguez, M; Gao, C; García-Closas, M; García-Sáenz, JA; Ghoussaini, M; Giles, GG; Goldberg, MS; González-Neira, A; Guénel, P; Gündert, M; Haeberle, L; Hahnen, E; Haiman, CA; Hall, P; Hamann, U; Hartman, M; Hatse, S; Hauke, J; Hollestelle, A; Hoppe, R; Hopper, JL; Hou, M-F; kConFab Investigators; ABCTB Investigators; Ito, H; Iwasaki, M; Jager, A; Jakubowska, A; Janni, W; John, EM; Joseph, V; Jung, A; Kaaks, R; Kang, D; Keeman, R; Khusnutdinova, E; Kim, S-W; Kosma, V-M; Kraft, P; Kristensen, VN; Kubelka-Sabit, K; Kurian, AW; Kwong, A; Lacey, JV; Lambrechts, D; Larson, NL; Larsson, SC; Le Marchand, L; Lejbkowicz, F; Li, J; Long, J; Lophatananon, A; Lubiński, J; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Matsuo, K; Mavroudis, D; Mayes, R; Menon, U; Milne, RL; Mohd Taib, NA; Muir, K; Muranen, TA; Murphy, RA; Nevanlinna, H; O'Brien, KM; Offit, K; Olson, JE; Olsson, H; Park, SK; Park-Simon, T-W; Patel, AV; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Presneau, N; Pylkäs, K; Rack, B; Rennert, G; Romero, A; Ruebner, M; Rüdiger, T; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Shah, M; Shen, C-Y; Shu, X-O; Simard, J; Southey, MC; Stone, J; Surowy, H; Swerdlow, AJ; Tamimi, RM; Tapper, WJ; Taylor, JA; Teo, SH; Teras, LR; Terry, MB; Toland, AE; Tomlinson, I; Truong, T; Tseng, C-C; Untch, M; Vachon, CM; van den Ouweland, AMW; Wang, SS; Weinberg, CR; Wendt, C; Winham, SJ; Winqvist, R; Wolk, A; Wu, AH; Yamaji, T; Zheng, W; Ziogas, A; Pharoah, PDP; Dunning, AM; Easton, DF; Pettitt, SJ; Lord, CJ; Haider, S; Orr, N; Fletcher, O
      A combination of genetic and functional approaches has identified three independent breast cancer risk loci at 2q35. A recent fine-scale mapping analysis to refine these associations resulted in 1 (signal 1), 5 (signal 2), ...
    • Functional characterization of E- and P-cadherin in invasive breast cancer cells 

      Sarrio, D; Palacios, J; Hergueta-Redondo, M; Gomez-Lopez, G; Cano, A; Moreno-Bueno, G (BIOMED CENTRAL LTD, 2009-03-03)
      Background: Alterations in the cadherin-catenin adhesion complexes are involved in tumor initiation, progression and metastasis. However, the functional implication of distinct cadherin types in breast cancer biology is ...
    • Functional coupling of transcription and splicing 

      Sanchez Alvarez, Miguel (2012-06)
      The tightly regulated process of precursor messenger RNA (pre-mRNA) alternative splicing is a key mechanism to increase the number and complexity of proteins encoded by the genome. Evidence gathered in recent years has ...
    • Functional Data Analysis Applied to Modeling of Severe Acute Mucositis and Dysphagia Resulting From Head and Neck Radiation Therapy. 

      Dean, JA; Wong, KH; Gay, H; Welsh, LC; Jones, A-B; Schick, U; Oh, JH; Apte, A; Newbold, KL; Bhide, SA; Harrington, KJ; Deasy, JO; Nutting, CM; Gulliford, SL (2016-11)
      <h4>Purpose</h4>Current normal tissue complication probability modeling using logistic regression suffers from bias and high uncertainty in the presence of highly correlated radiation therapy (RT) dose data. This hinders ...
    • Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. 

      Khan, K; Rata, M; Cunningham, D; Koh, D-M; Tunariu, N; Hahne, JC; Vlachogiannis, G; Hedayat, S; Marchetti, S; Lampis, A; Damavandi, MD; Lote, H; Rana, I; Williams, A; Eccles, SA; Fontana, E; Collins, D; Eltahir, Z; Rao, S; Watkins, D; Starling, N; Thomas, J; Kalaitzaki, E; Fotiadis, N; Begum, R; Bali, M; Rugge, M; Temple, E; Fassan, M; Chau, I; Braconi, C; Valeri, N (2018-08)
      <h4>Objective</h4>Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for ...
    • The functional importance of structure in unstructured protein regions. 

      Davey, NE (2019-06)
      After two decades of research, intrinsically disordered regions (IDRs) are established as a widespread phenomenon. The growing understanding of the significant functional role of IDRs has challenged the structure-function ...
    • Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. 

      Lawrenson, K; Kar, S; McCue, K; Kuchenbaeker, K; Michailidou, K; Tyrer, J; Beesley, J; Ramus, SJ; Li, Q; Delgado, MK; Lee, JM; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Arun, BK; Arver, B; Bandera, EV; Barile, M; Barkardottir, RB; Barrowdale, D; Beckmann, MW; Benitez, J; Berchuck, A; Bisogna, M; Bjorge, L; Blomqvist, C; Blot, W; Bogdanova, N; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Børresen-Dale, A-L; Brauch, H; Brennan, P; Brenner, H; Bruinsma, F; Brunet, J; Buhari, SA; Burwinkel, B; Butzow, R; Buys, SS; Cai, Q; Caldes, T; Campbell, I; Canniotto, R; Chang-Claude, J; Chiquette, J; Choi, J-Y; Claes, KBM; GEMO Study Collaborators; Cook, LS; Cox, A; Cramer, DW; Cross, SS; Cybulski, C; Czene, K; Daly, MB; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; Dennis, J; Devilee, P; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Dumont, M; Ehrencrona, H; Ejlertsen, B; Ellis, S; EMBRACE; Engel, C; Lee, E; Evans, DG; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Flyger, H; Foretova, L; Fostira, F; Foulkes, WD; Fridley, BL; Friedman, E; Frost, D; Gambino, G; Ganz, PA; Garber, J; García-Closas, M; Gentry-Maharaj, A; Ghoussaini, M; Giles, GG; Glasspool, R; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Goode, EL; Goodman, MT; Greene, MH; Gronwald, J; Guénel, P; Haiman, CA; Hall, P; Hallberg, E; Hamann, U; Hansen, TVO; Harrington, PA; Hartman, M; Hassan, N; Healey, S; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Heitz, F; Herzog, J; Høgdall, E; Høgdall, CK; Hogervorst, FBL; Hollestelle, A; Hopper, JL; Hulick, PJ; Huzarski, T; Imyanitov, EN; KConFab Investigators; Australian Ovarian Cancer Study Group; Isaacs, C; Ito, H; Jakubowska, A; Janavicius, R; Jensen, A; John, EM; Johnson, N; Kabisch, M; Kang, D; Kapuscinski, M; Karlan, BY; Khan, S; Kiemeney, LA; Kjaer, SK; Knight, JA; Konstantopoulou, I; Kosma, V-M; Kristensen, V; Kupryjanczyk, J; Kwong, A; de la Hoya, M; Laitman, Y; Lambrechts, D; Le, N; De Leeneer, K; Lester, J; Levine, DA; Li, J; Lindblom, A; Long, J; Lophatananon, A; Loud, JT; Lu, K; Lubinski, J; Mannermaa, A; Manoukian, S; Le Marchand, L; Margolin, S; Marme, F; Massuger, LFAG; Matsuo, K; Mazoyer, S; McGuffog, L; McLean, C; McNeish, I; Meindl, A; Menon, U; Mensenkamp, AR; Milne, RL; Montagna, M; Moysich, KB; Muir, K; Mulligan, AM; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Nord, S; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olswold, C; O'Malley, D; Orlow, I; Orr, N; Osorio, A; Park, SK; Pearce, CL; Pejovic, T; Peterlongo, P; Pfeiler, G; Phelan, CM; Poole, EM; Pylkäs, K; Radice, P; Rantala, J; Rashid, MU; Rennert, G; Rhenius, V; Rhiem, K; Risch, HA; Rodriguez, G; Rossing, MA; Rudolph, A; Salvesen, HB; Sangrajrang, S; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Sellers, TA; Seynaeve, C; Shah, M; Shen, C-Y; Shu, X-O; Sieh, W; Singer, CF; Sinilnikova, OM; Slager, S; Song, H; Soucy, P; Southey, MC; Stenmark-Askmalm, M; Stoppa-Lyonnet, D; Sutter, C; Swerdlow, A; Tchatchou, S; Teixeira, MR; Teo, SH; Terry, KL; Terry, MB; Thomassen, M; Tibiletti, MG; Tihomirova, L; Tognazzo, S; Toland, AE; Tomlinson, I; Torres, D; Truong, T; Tseng, C-C; Tung, N; Tworoger, SS; Vachon, C; van den Ouweland, AMW; van Doorn, HC; van Rensburg, EJ; Van't Veer, LJ; Vanderstichele, A; Vergote, I; Vijai, J; Wang, Q; Wang-Gohrke, S; Weitzel, JN; Wentzensen, N; Whittemore, AS; Wildiers, H; Winqvist, R; Wu, AH; Yannoukakos, D; Yoon, S-Y; Yu, J-C; Zheng, W; Zheng, Y; Khanna, KK; Simard, J; Monteiro, AN; French, JD; Couch, FJ; Freedman, ML; Easton, DF; Dunning, AM; Pharoah, PD; Edwards, SL; Chenevix-Trench, G; Antoniou, AC; Gayther, SA (2016-09-07)
      A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify ...
    • Functional phosphorylation sites in the C-terminal region of the multivalent multifunctional transcriptional factor CTCF 

      Klenova, EM; Chernukhin, IV; El-Kady, A; Lee, RE; Pugacheva, EM; Loukinov, DI; Goodwin, GH; Delgado, D; Filippova, GN; Leon, J; Morse, HC; Neiman, PE; Lobanenkov, VV (2001-03)
      CTCF is a widely expressed and highly conserved multi-Zn-finger (ZF) nuclear factor. Binding to various CTCF target sites (CTSs) is mediated by combinatorial contributions of different ZFs. Different CTSs mediate distinct ...